Evidence map›Paper›PMID 27032653›Full record

ArticleLung2016

Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.

Melike Demir, Halide Kaya, Mahsuk Taylan, Aysun Ekinci, Sureyya Yılmaz, Fatma Teke, Cengizhan Sezgi, Abdullah Cetin Tanrikulu, Fatih Meteroglu, Abdurrahman Senyigit

Abstract read
PubMed Publisher
In one paragraph

Article in Lung, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 4 pooled it
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2021
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Melike DemirDepartment of Chest Disease, Dicle University Faculty of Medicine, Sur, 21280, Diyarbakir, Turkey. melikedoktor@hotmail.com.
Halide KayaDepartment of Chest Disease, Dicle University Faculty of Medicine, Sur, 21280, Diyarbakir, Turkey.
Mahsuk TaylanDepartment of Chest Disease, Dicle University Faculty of Medicine, Sur, 21280, Diyarbakir, Turkey.
Aysun EkinciDepartment of Biochemistry, Dicle University Faculty of Medicine, 21280, Diyarbakir, Turkey.
Sureyya YılmazDepartment of Chest Disease, Dicle University Faculty of Medicine, Sur, 21280, Diyarbakir, Turkey.
Fatma TekeDepartment of Radiation Oncology, Dicle University Faculty of Medicine, 21280, Diyarbakir, Turkey.
Cengizhan SezgiDepartment of Chest Disease, Dicle University Faculty of Medicine, Sur, 21280, Diyarbakir, Turkey.
Abdullah Cetin TanrikuluDepartment of Chest Disease, Dicle University Faculty of Medicine, Sur, 21280, Diyarbakir, Turkey.
Fatih MeterogluDepartment of Thoracic Surgery, Dicle University Faculty of Medicine, 21280, Diyarbakir, Turkey.
Abdurrahman SenyigitDepartment of Chest Disease, Dicle University Faculty of Medicine, Sur, 21280, Diyarbakir, Turkey.
Dicle University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe purpose of this study was to investigate the potential value of certain biomarkers in predicting the presence of malignant pleural mesothelioma (MPM) in individuals environmentally exposed to asbestos.

methodsThis prospective study investigated three groups; a control group composed of 41 healthy subjects, an asbestos exposure group consisting of 48 individuals, and a MPM group consisting of 42 patients. Serum levels of soluble mesothelin-related peptide (SMRP), thioredoxin-1 (TRX), epidermal growth factor receptor (EGFR), fibulin-3, syndecan-1 (SDC-1), and mesothelin were determined.

resultsBenign pleural plaques were present in 27 (58.3 %) of the individuals in the asbestos exposure group. The asbestos exposure group had significantly higher mean TRX, SMRP, and mesothelin levels compared to the control group (p = 0.023, p = 0.011, and p < 0.001, respectively). Compared to the asbestos exposure group, the MPM group had significantly higher mean EGFR, TRX, SMRP, and fibulin-3 levels (p = 0.041, p = 0.023, p = 0.002, and p = 0.001, respectively), and significantly lower mean SDC-1 levels (p = 0.002). Unlike the other biomarkers, SMRP and TRX levels increased in a graded fashion among the control, asbestos exposure, and MPM groups, respectively. Area under the curve values for SMRP and TRX were 0.86 and 0.72, respectively (95 % CI 0.79-0.92 and p < 0.001 for SMRP, and 95 % CI 0.62-0.81 and p < 0.001 for TRX). The cut-off value for SMRP was 0.62 nmol/l (sensitivity: 97.6 %, specificity: 68.9 %, positive predictive value (PPV): 56.2 %, and negative predictive value (NPV): 98.3 %) and for TRX was 156.67 ng/ml (sensitivity: 92.9 %, specificity: 77.6 %, PPV: 41.4 %, and NPV: 92.1 %). The combination of the biomarkers reached a sensitivity of 100 %, but had lower specificity (as high as 27.7 %).

conclusionsSerum biomarkers may be helpful for early diagnosis of MPM in asbestos-exposed cases. SMRP and TRX increased in a graded fashion from the controls to asbestos exposure and MPM groups. These two seem to be the most valuable biomarkers for the diagnosis of MPM, both individually and in combination.

Indexed as

Environmental ExposureAgedArea Under CurveAsbestosBiomarkers, TumorCase-Control StudiesErbB ReceptorsExtracellular Matrix ProteinsFemaleGPI-Linked ProteinsHumansMaleMesothelinMesotheliomaMiddle AgedPeptidesAsbestosBiomarkers, TumorEFEMP1 protein, humanErbB ReceptorsExtracellular Matrix ProteinsGPI-Linked ProteinsMesothelinPeptidesSDC1 protein, humanSyndecan-1ThioredoxinsTXN protein, humanAsbestosBiomarkersMalignant pleural mesotheliomaSoluble mesothelin-related peptideThioredoxin-1

Identifiers

PMID27032653
OpenAlexW2330767862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.